126
Participants
Start Date
August 15, 2024
Primary Completion Date
August 31, 2025
Study Completion Date
August 31, 2025
Terlipressin
1\. Patients in this group will receive continuous terlipressin infusion (1 mg/24 hr on day 1, increasing to 1 mg in 24 hours if target MAP not achieved ,reaching maximum terlipressin dose of 4 mg/24 hr on day 4).If target MAP not achieved by terlipressin dose ,increase noradrenaline dose keeping terlipressin maximum 1 mg ,2 mg ,3mg ,4mg at Day 1,2,3,4 respectively.
Norephrine
1\. Patients in this group will receive norepinephrine only, with a dose range of 0.05 mcg/kg/min to 0.5 mcg/kg/min to maintain a MAP \> 65 to 75 mm Hg.
Institute of Liver & Biliary Sciences (ILBS), New Delhi
Institute of Liver and Biliary Sciences, India
OTHER